7,892 Amgen Inc. $AMGN Shares Bought by Frank Rimerman Advisors LLC

Frank Rimerman Advisors LLC increased its holdings in Amgen Inc. (NASDAQ:AMGN) by 108.5% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 15,164 shares of the medical research company’s stock after buying an additional 7,892 shares during the period. Frank Rimerman Advisors LLC’s holdings in Amgen were worth $6,392,000 as of its most recent SEC filing.

A number of other hedge funds have also bought and sold shares of the business. State Street Corp grew its position in Amgen by 38.2% during the second quarter. State Street Corp now owns 42,205,243 shares of the medical research company’s stock worth $15,283,363,000 after buying an additional 11,656,755 shares in the last quarter. Bank of America Corp DE bought a new position in Amgen in the 2nd quarter worth about $1,831,903,000. Wellington Management Group LLP increased its stake in Amgen by 1,102.7% in the 2nd quarter. Wellington Management Group LLP now owns 2,742,271 shares of the medical research company’s stock worth $993,031,000 after acquiring an additional 2,514,254 shares during the last quarter. BlackRock Inc. raised its holdings in shares of Amgen by 4.8% in the 2nd quarter. BlackRock Inc. now owns 49,362,016 shares of the medical research company’s stock valued at $17,874,974,000 after acquiring an additional 2,261,544 shares in the last quarter. Finally, Assenagon Asset Management S.A. raised its holdings in shares of Amgen by 702.8% in the 3rd quarter. Assenagon Asset Management S.A. now owns 1,535,257 shares of the medical research company’s stock valued at $647,126,000 after acquiring an additional 1,344,010 shares in the last quarter. 76.50% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on AMGN shares. Royal Bank Of Canada lifted their price target on Amgen from $400.00 to $430.00 and gave the company an “outperform” rating in a research report on Thursday, October 8th. Canaccord Genuity Group upped their price objective on shares of Amgen from $366.00 to $384.00 and gave the stock a “hold” rating in a research report on Wednesday, August 5th. Weiss Ratings raised shares of Amgen from a “buy (b)” rating to a “buy (b+)” rating in a research note on Thursday, October 8th. Mizuho raised their target price on shares of Amgen from $303.00 to $352.00 and gave the company a “neutral” rating in a research note on Tuesday, August 18th. Finally, HSBC lowered shares of Amgen from a “buy” rating to a “hold” rating and dropped their target price for the company from $445.00 to $425.00 in a research report on Thursday, September 10th. One analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, sixteen have issued a Hold rating and three have assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and an average price target of $387.93.

Insider Transactions at Amgen

In other Amgen news, SVP Nancy A. Grygiel sold 2,970 shares of the company’s stock in a transaction that occurred on Thursday, August 6th. The stock was sold at an average price of $402.16, for a total value of $1,194,415.20. Following the completion of the sale, the senior vice president owned 7,340 shares of the company’s stock, valued at $2,951,854.40. This represents a 28.81% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Rachna Khosla sold 2,000 shares of the company’s stock in a transaction that occurred on Tuesday, August 11th. The stock was sold at an average price of $412.57, for a total value of $825,140.00. Following the completion of the sale, the senior vice president directly owned 6,404 shares of the company’s stock, valued at approximately $2,642,098.28. This represents a 23.80% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders have sold 6,222 shares of company stock worth $2,540,926. 0.85% of the stock is currently owned by insiders.

Amgen Stock Down 0.4%

AMGN opened at $432.49 on Friday. The stock has a market cap of $233.82 billion, a PE ratio of 26.88, a P/E/G ratio of 3.17 and a beta of 0.41. The company has a quick ratio of 1.13, a current ratio of 1.37 and a debt-to-equity ratio of 4.44. Amgen Inc. has a 52 week low of $288.00 and a 52 week high of $447.03. The business’s fifty day simple moving average is $415.54 and its 200 day simple moving average is $374.76.

Amgen (NASDAQ:AMGN) last released its quarterly earnings results on Tuesday, August 4th. The medical research company reported $6.29 earnings per share for the quarter, beating analysts’ consensus estimates of $5.62 by $0.67. Amgen had a return on equity of 124.14% and a net margin of 22.95%. The business had revenue of $10.05 billion for the quarter, compared to the consensus estimate of $9.43 billion. During the same quarter last year, the business posted $6.02 earnings per share. The company’s revenue for the quarter was up 9.5% on a year-over-year basis. Amgen has set its FY 2026 guidance at 22.300-23.500 EPS. As a group, research analysts expect that Amgen Inc. will post 22.94 earnings per share for the current fiscal year.

Amgen Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Friday, September 11th. Stockholders of record on Friday, August 21st were given a dividend of $2.52 per share. The ex-dividend date was Friday, August 21st. This represents a $10.08 annualized dividend and a dividend yield of 2.3%. Amgen’s dividend payout ratio is 62.65%.

Amgen Profile

Amgen Inc is a biotechnology company that discovers, develops, manufactures and delivers medicines for serious illnesses. Its research focuses on areas including oncology, cardiovascular disease, inflammation, bone health, nephrology and neuroscience.

The company’s products include biologic and specialty medicines such as Enbrel for inflammatory diseases, Prolia and Evenity for osteoporosis, Xgeva for skeletal-related complications, Repatha for cardiovascular risk reduction, Otezla for inflammatory conditions, Tezspire for severe asthma, Blincyto for certain blood cancers, and Lumakras for specific cancers.

Founded in 1980, Amgen is headquartered in Thousand Oaks, California.